Skip to content
Tenfell
Awarded contract
Published 20 Oct 2021

NHS National Pharmaceuticals - Everolimus and terminated agreement products

NHS England · London

Key facts

Awarded
07 Jun 2021
Contract starts
14 May 2021
Contract ends
01 Mar 2022
Procedure
Accelerated Open procedure (above threshold)
Buyer type
Central government

Awarded to 15 suppliers

SupplierValue
FRESENIUS KABI LIMITED—
Bowmed Ibisqus Limited—
Crescent Pharma Limited—
Dr Reddy's Laboratories (UK) Ltd—
Martindale Pharma—
Ranbaxy (UK) Ltd—
Teva UK Ltd—
Selective Supplies Ltd—
Accord-UK Ltd—
Mylan—
Drugsrus Ltd—
Milpharm Ltd/aurobinbdo—
Torrent Pharma UK Ltd—
Medreich PLC—
Bristol Laboratories Limited—

Description

Invitation to offer for NHS National Pharmaceuticals - Everolimus and terminated agreement products Offer reference number: CM/PHG/21/5632 Period of framework agreement: Start date to be confirmed with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Potential periods of call-offs under the framework agreement:

Everolimus: All regions: to commence as soon as possible with an end date of 01/03/2022 Oral Products: All regions: to commence as soon as possible with an end date of 28/02/2022 Hospital Only Products: DLS, DNE, DNW, DLN and DSW regions: to commence as soon as possible with an end date 31/01/2022

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.